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Background: Due to their efficacy and tolerability, utilization of proton pump inhibitors
(PPI) has significantly increased worldwide. Parallel to the clinical benefits, potential long-
term side effects have been observed, which, along with increasing medical expenses and
potential drug interactions, justifies the analysis of the trends of utilization.
Objective: The aim of the present study was to show the level, pattern, and characteristics
of PPI use.
Methods:We assessed the nationwide use of proton pump inhibitors in ambulatory care
based on aggregated utilization data from the National Health Insurance database. The
annual PPI utilization was expressed as the number of packages and as number of DDDs
per 1,000 inhabitants and per year. For 2018, we estimated PPI exposure as the number
of packages and as the number of DDDs per user per year. The annual reimbursement
costs of proton pump inhibitors were also calculated. Moreover, three patient-level
surveys were carried out in non-gastroenterological inpatient hospital departments to
reveal characteristics of proton pump inhibitor use, namely dose, duration, and indication.
Results: The PPI utilisation increased from 5867.8 thousand to 7124.9 thousand
packages and from 41.9 to 50.4 DDD per 1,000 inhabitants and per day between
2014 and 2018. Nationwide data showed that 14% of the adult population was exposed
to proton pump inhibitors in 2018, while among hospitalized patients, the prevalence of
proton pump inhibitor use was between 44.5% and 54.1%. Pantoprazole was the most
frequently used active ingredient, both in the nationwide data and in the patient-level
surveys. In the patient-level survey in majority of patients (71.5%–80.0%) proton pump
inhibitors were prescribed for prophylaxis. Many inpatients (29.4%–36.9%) used 80 mg
pantoprazole per day. The average number of PPI packages per user was 6.5 in 2018 in
the nationwide data. The duration of PPI therapy was typically between 1 and 5 years in
the patient-level surveys and nearly 20% of the inpatients had been taking proton pump
inhibitors for more than 5 years.in.org September 2020 | Volume 11 | Article 5521021
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Frontiers in Pharmacology | www.frontiersConclusions: Our data suggests that Hungarian patients receive proton pump inhibitors
in high doses and for a long time. Use of proton pump inhibitors beyond their
recommended indications was also found.Keywords: proton pump inhibitors, proton pump inhibitors exposure, proton pump inhibitors dose, proton pump
inhibitors therapy duration, nationwide data, patient-level surveyINTRODUCTION
In the 1990s, widespread use of proton pump inhibitors
(PPIs) radically changed the treatment of acute and chronic
gastroenterological diseases caused by hyperacidity (Garner
et al., 1996; Savarino et al., 2018a). Different PPI products have
an equivalent mechanism of action and a similar clinical efficacy
(Strand et al., 2017). Due to their excellent efficacy, tolerability and
positive adverse event profile, PPI utilization has significantly
increased all over the world (Hollingworth et al., 2010; Tett
et al., 2013; Lanas, 2016; Ying et al., 2019). Besides official,
evidence-based use of PPIs, less understandable and justifiable
prescriptions have also occurred (Savarino et al., 2017; Savarino
et al., 2018a). More than 10 years ago, additional costs resulting
from PPI overuse were estimated to be 2 billion pounds worldwide
(Forgacs and Loganayagam, 2008).
Parallel to the clinical benefits of long-term PPI therapy in
some clinical conditions (e.g. severe erosive esophagitis, Barett’s
esophagus), potential side effects have also been observed,
especially among the elderly (Maleth and Hegyi, 2013;
Freedberg et al., 2017; Maes et al., 2017; Yu et al., 2017;
Haastrup et al., 2018; Igaz et al., 2018; Devitt et al., 2019;
Lanas-Gimeno et al., 2019). Some of these are controversial
and based on extremely loose associations (e.g. dementia,
chronic nephropathy), while others (e.g. enteral infections,
micronutrient deficiency) have been confirmed by sound
evidence (Bajor, 2017; Strand et al., 2017; Ayele et al., 2018;
Schubert, 2018; Schubert, 2019).
Potential long-term side effects, increasing medical expenses,
and potential drug interactions (Hu et al., 2018) justify the
recognition and analysis of the trends and characteristics of
PPI utilization. Utilization of PPIs has been analyzed in many
countries (Pillans et al., 2000; Chia et al., 2014; Larsen et al., 2014;
Kelly et al., 2015; Meli et al., 2015; Lodato et al., 2016; Pottegard
et al., 2016; Pujal Herranz, 2016; Juntunen et al., 2017; Del
Giorno et al., 2018; Halfdanarson et al., 2018; Luo et al., 2018;
Ying et al., 2019), but no data from Hungary has been published
yet, as emphasized in the study of Igaz et al. (2018). The aim of
the present study was to show the level, pattern, and
characteristics of PPI use, using mixed methods.METHODS
National Data
The source of annual national drug utilization data was the public,
aggregated report of the National Health Insurance Fund of
Hungary (Hungarian acronym: NEAK) (2014–2018). This report
contains information on all dispensed and reimbursed prescriptionin.org 2drugs in Hungary. As NEAK is the sole and mandatory health
insurance agency in Hungary, it covers 100% of the population.
Over the counter dispensations (including some PPI products), and
non-reimbursed drugs are not included in the dataset.
The reimbursement rate is 55% for all PPI substances,
regardless of the indication and the prescriber. Only the
products with the highest price (usually the originator) are
excluded from the reimbursement status. Currently, there are
eleven PPI products that are available without prescription (nine
products containing 20 mg pantoprazole and two products
containing 20 mg esomeprazole), all the other PPI products
(N=74) are prescription-only. General practitioners can initiate
and prescribe PPI therapy with a similar reimbursement rate
as gastroenterologists.
PPIs were classified using the WHO ATC [World Health
Organisation (WHO), 2020] methodology (version 2020). PPI use
was expressed as the number of annual packages and as WHO
defined daily doses (DDD, version 2020) standardized for the
population (i.e. DDD per 1,000 inhabitants and per
day). Furthermore, regarding certain PPI active ingredients (ATC
subgroup A02BC), for the year 2018, we determined the average
number of packages per user per year and the average number of
DDDs per user per year. The public drug utilization report of NEAK
includes reimbursement costs. Summarizing these numbers, we
calculated the annual reimbursement cost of PPIs.Patient-Level Surveys
Three patient-level cross-sectional surveys were carried out in
inpatient hospital departments. For Surveys 1 and 2, all hospital
pharmacists were invited from hospitals (N=12) where daily dose
drug dispensation was supervised by a pharmacist and medical
reconciliation practice was in place in 2016. This is approximately
10% of all Hungarian hospitals. Out of the 12 hospitals, 10 agreed
to take part in the survey. To enable generaliability the surveys
were conducted in adult departments (N=29) of these hospitals
with a non-gastroenterological profile, to exclude units where
acid-related diseases are specifically treated. Intensive care units
and psychiatry units were not included as communication with the
patient is difficult/not possible that may introduce response bias.
The most important characteristics of the surveys are shown in
Table 1. The different surveys consecutively followed each other,
and revealed progressively more characteristics of PPI use (e.g.
Survey 1 did not assess duration of PPI use, but Surveys 2 and 3
did). The precise overall medication regimen was recorded in
Survey 3. All adult (age 18 years or above), cooperative inpatients
on the specific study days were included in the surveys to avoid
selection bias. On the specific study days, the responsible ward
pharmacist recorded medication use from medical records (thatSeptember 2020 | Volume 11 | Article 552102
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consulted the patients about PPI indication, therapy duration,
etc. In Survey 3, the initiation of PPI therapy was also asked from
the patient (GP or specialist).
According to sample size calculations, at least 300–400 responses
were required to estimate the occurance of non-rare events, such as
PPI use. Due to further stratification of data we sought for a higher
sample size in the multicenter surveys (Surveys 1 and 2).
The data sheet for anonymous data collection contained
demographic data and characteristics (active ingredient, daily
dose, etc.) of PPI treatment. In all surveys, data were obtained
during the medication reconciliation process. Polypharmacy was
defined as taking five or more concomitant medications
chronically (Duerden et al., 2013). Descriptive statistics were
used with measures of central tendency (mean) and spread of the
distribution (standard deviations minimum-maximum range).
Data processing and evaluation were carried out using MS Office
and R.3.5.1. software.RESULTS
National Data
In 2018, a total of 7.12 million PPI packages were prescribed and
dispensed, which corresponds to 730 packages per 1000
inhabitants, while in 2014, these numbers were under 5.87
million packages and 600 packages per 1000 inhabitants.
Expressing the utilisation in DDD per 1,000 inhabitants and
per day, it increased from 41.9 to 50.4 (see Table 2B). Over the
last 5 years, PPI utilization has shown an upward trend, which is
mostly due to an increase in pantoprazole use (Table 2A).
Assuming that no active agent switch occurred, nearly 1.1
million Hungarian inhabitants were exposed to PPIs. This
represents 14% of the adult population aged 18 years or above.
Every year (2014–2018), more than half of the used PPIs
contained pantoprazole as the active ingredient. In 2018, more
than 663,000 inhabitants redeemed at least one package of a
pantoprazole product (Table 3), which means that 7% of the
Hungarian population (including children) was exposed to
pantoprazole. Considering the annual number of packages, the
average number of packages per user in case of pantoprazole
products was almost 7 (6.9) in 2018. Since in most cases, oneFrontiers in Pharmacology | www.frontiersin.org 3package equals 1 month of PPI use, this suggests average long-
term PPI therapy of up to 6 to 8 months.
Due to generic competition, the previous decade brought a
significant price reduction of PPIs, but still the National Health
Insurance Fund of Hungary reimbursed 1622 million forints (5.1
million Euros) for these products in 2018 (Table 4).
Patient-Level Surveys
The results are summarized in Table 5 and Table 6. Among the
hospitalized patients, the prevalence of PPI utilization was
around 50% (ranged between 44.5% and 54.1% in different
surveys), and all patients were on oral PPI therapy. Up to
21.5% of the patients had been put on PPI therapy during
hospitalization (Table 5). However, in all surveys, most of the
patients only continued their previously prescribed PPI
treatment. PPI therapy was initiated by a general practitioner
in 81.5% of cases, and in only a few cases was PPI treatment
started by a gastroenterologist (Survey 3).
The average age of patients in all surveys was >65 years. The
prevalence of polypharmacy among PPI users was >70%. In all
surveys, the most commonly used active ingredient was
pantoprazole. The prescribed daily dose of pantoprazole varied
from 20 mg to 160 mg. According to our survey data, most
patients received 40 mg (43.1%−48.4%) or 80 mg pantoprazole
(29.4%–36.9%) per day (Table 6). Duration of PPI therapy was
typically between 1 and 5 years. Nearly 20% of the patients had
been taking PPIs for more than 5 years. None of the patients
reported an attempt to de-prescribe (Survey 3).
In 20% of the cases, the indication for PPI utilization was
therapy in all three surveys, mostly for gastro-esophageal reflux
or peptic ulcer. However, most patients received PPI as
prevention. Most patients had other diseases besides the main
reason for their hospitalization, which is not surprising
considering their average age. This means that most patients
were on polypharmacy and PPIs were prescribed as prevention
against potential gastric mucosal irritation caused by other
medications (see indications in Table 5).
Applying a conservative estimate, in Survey 2, of the 399 PPI
users, 66 patients (16.5%) did not have any therapeutic indication
for PPI use, and also had not used any potentially ulcerogenic or
anticoagulant/antiplatelet drug. Similarly, most patients in Survey 3
received clopidogrel therapy, but only a few of them had alsoTABLE 1 | Methodological characteristics of patient-level Surveys 1, 2, and 3.
Survey 1 Survey 2 Survey 3
Survey Date(s) 27 July 2016 25 January 2017 April 2017–March 2018
On 12 appointed days
(1 day per 3–4 weeks)
Survey Design point prevalence point prevalence (on multiple days)
Survey Site 29 wards from 10 hospitals
surgical, trauma, neurological, or dermatological wards
(10 outside the capital; 19 in the capital)
vascular surgery ward
Dosing of PPI therapy recorded recorded recorded
Indication of PPI therapy recorded recorded recorded
Duration of PPI therapy not recorded recorded recorded
Initiation of PPI use not recorded only hospital initiation recorded
De-prescribing attempt not recorded not recorded recorded
Total number of the patient’s chronic medications not recorded recorded recordedSeptember 2020 | Volume 11 | Article 552102
Matuz et al. PPI Use in Hungaryreceived NSAID treatment, or had had a history of peptic ulcer or
bleeding prior to hospitalization. Dual antiplatelet therapy
administration occurred in up to 27.7% of the patients taking
PPIs (Table 5).
DISCUSSION
Due to the superiority of PPIs over H2 receptor blockers in both
effectiveness and pharmacokinetics, their use soon replaced H2Frontiers in Pharmacology | www.frontiersin.org 4receptor blockers in the treatment of gastroenterological diseases
caused by increased hydrochloric acid secretion [van Pinxteren
et al., 2006; Kahrilas et al., 2008; National Institute for Health and
Care Excellence (NICE), 2014; Iwakiri et al., 2016; Brunton,
2017; Savarino et al., 2017]. In addition, increased awareness of
ulcer prophylaxis requirements has resulted in endless expansion
of the PPI market (Savarino et al., 2017).
Besides official, evidence-based indications for PPI treatment
and prophylaxis, unjustifiable prescriptions occurred in clinicalTABLE 2A | Utilization of certain proton pump inhibitors (PPIs’) over the last 5 years in Hungary (organized in descending order based on the data from 2018)—number
of packages.
ATC Active Ingredient 1,000 packages (share in %) trend
2014 2015 2016 2017 2018
A02BC02 pantoprazole 3171.74 3842.92 4144.39 4444.86 4603
(54.05) (58.22) (60.68) (62.21) (64.60)
A02BC05 esomeprazole 1101.76 1210.43 1241.44 1307.98 1282.82
(18.78) (18.34) (18.18) (18.31) (18.00)
A02BC04 rabeprazole 768.73 742.15 696.3 673.08 596.48
(13.10) (11.24) (10.19) (9.42) (8.37)
A02BC03 lansoprazole 630.61 586.23 538.59 495.21 417.06
(10.75) (8.88) (7.89) (6.93) (5.85)
A02BC01 omeprazole 194.97 218.66 209.74 223.58 225.52
(3.32) (3.31) (3.07) (3.13) (3.17)
All PPIs (A02AB) 5867.8 6600.4 6830.47 7144.72 7124.88
(100.00) (100.00) (100.00) (100.00) (100.00)September 2020 | VolumeTABLE 2B | Utilization of certain proton pump inhibitors (PPIs’) over the last 5 years in Hungary (organized in descending order based on the data from 2018)—defined
daily dose (DDD) per 1,000 inhabitants and per day.
ATC Active Ingredient DDD per 1,000 inhabitants and per day (share in %) trend
2014 2015 2016 2017 2018
A02BC02 pantoprazole 21.06 25.78 28.03 29.36 30.04
(50.27) (54.41) (56.87) (57.62) (59.64)
A02BC05 esomeprazole 9.33 10.33 10.60 11.21 11.04
(22.28) (21.80) (21.5) (21.99) (21.91)
A02BC04 rabeprazole 5.54 5.38 5.12 5.00 4.42
(13.22) (11.36) (10.40) (9.82) (8.77)
A02BC03 lansoprazole 4.36 4.08 3.78 3.51 2.97
(10.41) (8.61) (7.67) (6.88) (5.89)
A02BC01 omeprazole 1.60 1.81 1.75 1.88 1.91
(3.82) (3.82) (3.55) (3.69) (3.79)
All PPIs (A02AB) 41.88 47.37 49.29 50.96 50.37
(100.00) (100.00) (100.00) (100.00) (100.00)11TABLE 3 | Annual proton pump inhibitor (PPI) use in packages and in DDDs in 2018, number of proton pump inhibitor users of certain active ingredients, and sales
standardized by number of users (based on the public database of the National Health Insurance Fund of Hungary).
ATC Active Ingredient Package number Number of DDDs Number of PPI users* Average package number
per user per year
Average number of DDDs
per user per year
A02BC01 omeprazole 225 518 6 817 868 54 739 4.12 124.55
A02BC02 pantoprazole 4 603 004 107 216 453 663 339 6.94 161.63
A02BC03 lansoprazole 417 055 10 595 214 57 440 7.26 184.46
A02BC04 rabeprazole 596 482 15 763 302 94 218 6.33 167.31
A02BC05 esomeprazole 1 282 824 39 386 331 226 502 5.66 173.89
All PPI (A02AB) 7 124 883 179 779 168 **1 096 238 6.50 164.00*user: person who purchased a prescribed proton pump inhibitor product (of the given active ingredient) at least once a year.
**: estimation as sum of individual active agents users.| Article 552102
Matuz et al. PPI Use in Hungarypractice (Savarino et al., 2017; Savarino et al., 2018a). A review
found the mean rate of PPI overuse was 57% in hospitals, and
50% in primary care settings (Savarino et al., 2017).
Prevalence of PPI Utilization
Based on national data, it was estimated that 14% of the Hungarian
adult population was exposed to PPIs in outpatient care per year,
while in adult hospital inpatients, this number was considerably
higher, nearly 50%. Lower exposure was found in a Danish
nationwide study, where gradual increase of PPI use was detected,
and 7.4% of the adult population was exposed to PPIs in 2014. The
high exposure of Hungarian patients to PPIs can be explained by the
fact that PPI therapy can also be initiated by General practitioners
(GPs) who can prescribe PPIs as gastroenterologists (i.e. with the
same reimbursement rate). The high prevalence of PPI use (nearly
50% or above) among hospitalized patients has previously been
reported in other countries as well (Chia et al., 2014; Kelly et al.,
2015; Meli et al., 2015; Lodato et al., 2016; Pujal Herranz, 2016; Del
Giorno et al., 2018).
Active Ingredient/Pharmaceutical Form/
Dosing of PPIs/Expenses
In Hungary (as in Denmark), pantoprazole was the most
frequently prescribed and dispensed PPI, while in Iceland,
omeprazole and esomeprazole were the most frequently used
PPIs (Pottegard et al., 2016; Halfdanarson et al., 2018). The
dominance of pantoprazole in Hungary can be explained by the
high number of generic products and their consequent lower
price compared to other PPI agents.
Every third patient in our study was on a high dose pantoprazole
regimen, despite the fact that only those with extra-esophageal
gastro-esophageal reflux symptoms (Zollinger–Elisson syndrome)
require higher than standard dose PPI treatment (Savarino et al.,
2018a). The high rate of high-dose pantoprazole treatment can be
explained by the general suboptimal practice that despite the longer
duration of action due to the irreversible inhibition of the proton
pump, similarly to H2 receptor antagonists, doctors often prescribe
PPI to be taken twice daily regardless of indication.
Moreover, in the most common indications for PPIs
(symptomatic gastro-esophageal reflux, maintenance therapy of
reflux esophagitis, or gastro protection with concomitant NSAIDFrontiers in Pharmacology | www.frontiersin.org 5use), 20 mg pantoprazole (low dose) is recommended in the
summary of product characteristics. In the Icelandic study, 95%
of patients started high dose PPI (they defined this “high dose”
category as standard dose or high dose), and 21% remained on
that treatment after 1 year (Halfdanarson et al., 2018). Similar
overdosing of PPIs has been reported from China (Ying
et al., 2019).
Despite the continuous increase in PPI utilization in the study
period, the reimbursement costs have decreased. The Hungarian
reimbursement system is very complex and under continuous
change (e.g. new prices are published monthly). During the five
study years, the continuous growth in the number of available
products (mainly pantoprazole) in the market generated a
considerable price competition and lower reimbursement costs.
Duration of PPI Use
Based on nationwide ambulatory drug use data, we estimated that
each PPI user took PPIs for more than half a year on average. In the
patient-level surveys, we observed that most patients were on PPI
therapy for more than a year, and every fifth patient received PPI for
more than 5 years. One possible explanation for the long duration of
PPI treatment can be the lack of national guidelines on PPI use and
PPI de-prescribing, and lack of medication review service provided
by pharmacists. As the average age of PPI users admitted to the
hospital was >65 years in all patient-level surveys, our data is similar
to the findings of Halfdanarson et al., who reported remarkably
higher PPI therapy duration in the elderly (Halfdanarson et al.,
2018). Prolonged treatment was observed in other studies. In a
Danish study, 44% of PPI users received PPI therapy for at least 3
years (Pottegard et al., 2016), while in Iceland 22% of PPI users
remained on PPI treatment after 1 year (Halfdanarson et al., 2018).
Appropriate duration of PPI use varies for different indications, but
in general, it rarely exceeds 3 months in clinical guidelines
(Halfdanarson et al., 2018). According to the newest National
Institute for Health and Care Excellence guideline (National
Institute for Health and Care Excellence (NICE), 2014), for the
vast majority of patients with gastro-esophageal reflux [those
without severe erosive esophagitis, Barrett’s Esophagus, or dilation
of esophageal stricture) short-term PPI treatment is recommended
for a maximum of 8 weeks (National Institute for Health and Care
Excellence (NICE), 2014].TABLE 4 | Reimbursement cost of proton pump inhibitors and reimbursement share of individual PPIs.
ATC Active Ingredient Reimbursement—million Hungarian forint—(%)
2014 2015 2016 2017 2018
A02BC01 omeprazole 401.45
(15.50)
349.41
(15.27)
44.00
(4.07)
40.93
(3.63)
98.29
(6.06)
A02BC02 pantoprazole 475.77
(18.37)
578.39
(25.28)
617.04
(57.06)
659.19
(58.42)
738.16
(45.51)
A02BC03 lansoprazole 241.72
(9.33)
190.65
(8.33)
81.47
(7.53)
76.07
(6.74)
97.11
(5.99)
A02BC04 rabeprazole 475.04
(18.34)
376.68
(16.46)
110.36
(10.21)
108.57
(9.62)
177.23
(10.93)
A02BC05 esomeprazole 996.07
(38.46)
793.06
(34.66)
228.55
(21.13)
243.58
(21.59)
511.16
(31.52)
All PPI (A02AB) 2590.04
(100.00)
2288.18
(100.00)
1081.43
(100.00)
1128.34
(100.00)
1621.95
(100.00)September 2020 | Volume 11 | Article 552102
Matuz et al. PPI Use in HungaryThe estimated overall prevalence of gastro-esophageal reflux,
the most common indication for PPI use, is around 9%–26% in
the European population (El-Serag et al., 2014). The prevalence
of diseases requiring long-term PPI use is low (Savarino et al.,
2018a; Savarino et al., 2018b): e.g. severe erosive esophagitis (Los
Angeles grade C/D) 0.5%, Barrett’s esophagus with confirmed
intestinal metaplasia 1.6%, while Zollinger Ellison syndrome is a
rare disease (Ronkainen et al., 2005a; Ronkainen et al., 2005b).
Considering continuous, long-term use of PPIs without the
supervision of a gastroenterologist, duration of therapy is
particularly alarming, since adverse events (e.g. Clostridioies
difficile infection) may develop due to persistent PPI utilization,Frontiers in Pharmacology | www.frontiersin.org 6and the economic burden is also substantial (Bajor, 2017; Savarino
et al., 2017; Ayele et al., 2018; Devitt et al., 2019).Initiation/De-Prescribing PPIs
Despite the fact that PPIs are available as Over the Counter
products in Hungary, in none of the surveyed patients was the
PPI therapy initiated by the patients themselves. According to
Survey 3, which also assessed who initiated PPI use, most PPI
regimens were started by GPs. In Iceland, GPs were also
responsible for 60% of the PPI use (Halfdanarson et al., 2018). In
Survey 2, which gathered data from 29 units, PPIs were initiated
during the hospital stay in 20% of cases. Another US study
evaluating PPI use at hospital admission and discharge found a
higher rate of PPI continuation upon discharge (Gupta et al., 2010).
As the prescribed drug regimen during the hospital stay is indicated
on the discharge letter, this guides GPs to automatically continue
prescribing PPIs. Pharmacist intervention could significantly
promote rational PPI use in the hospital setting (Luo et al., 2018)
by decreasing inappropriate indications, dosages and durations, so
their medical reconciliation before discharge should be promoted
to avoid irrational long-term PPI use.
According to the newest National Institute for Health and Care
Excellence guideline [National Institute for Health and Care
Excellence (NICE), 2014], periodic medication reviews are
needed if PPI treatment is prolonged. The American guidelines
also emphasize the need for de-prescribing, including using the
lowest effective dose (Freedberg et al., 2017). De-prescribing
guidelines are available for patients with uncomplicated, mild-
moderate gastro-esophageal reflux disease who completed a
minimum of 4 weeks of PPI therapy, and responded to it
(Farrell et al., 2017; Freedberg et al., 2017). In our survey, none
of the patients reported an attempt at de-prescribing. Automatic
renewal of prescriptions without re-evaluation of patient
symptoms is of great concern, as, without upper gastrointestinal
endoscopy to confirm the presence of erosive esophagitis, long-
term use of PPIs is debatable (Lassen et al., 2004). Also,
ambulatory pH/impedance monitoring may help to distinguish
gastro-esophageal reflux disease from a functional syndrome, and
consequently avoid lifelong PPI therapy (Freedberg et al., 2017).TABLE 5 | Patient-level survey results.
Survey 1 Survey 2 Survey 3
PPI users/all patients 382/706 399/864 65/146
prevalence (%) 54.11 46.18 44.52
95% confidence interval 50.42–57.75 42.88–49.51 36.70–52.62
Sex ratio (males per females) 183:199 192: 207 32:33
Males % 47.91 48.12 49.23
Age: mean ± SD 68.62 ± 15.11 69.59 ± 14.21 65.69 ± 11.56
min-max 18–96 23–98 31–86
Polypharmacy in the PPI user
group (number of patients)
unknown 343 59
% 85.96 73.29
Administered active
ingredient: number of patients
(%)
Pantoprazole 366 (95.81) 384 (96.24) 51 (78.46)
Lansoprazole 2 (0.52) 2 (0.5) 8 (12.31)
Rabeprazole 2 (0.52) 3 (0.75) 5 (7.69)
Omeprazole 3 (0.79) 2 (0.5) 0 (0.00)
esomeprazole 9 (2.36) 8 (2.01) 1 (1.54)
Duration of PPI treatment:
number of patients (%)
unknown
started during
hospitalization/after admission
84 (21.05) 0 (0.00)
less than 1 year 99 (24.81) 3 (4.62)
1 to 5 years 125 (31.33) 48 (73.85)
more than 5 years 82 (20.55) 14 (21.54)
missing
answer: nine
people
Indication of PPI utilization:
number of patients (%)
Therapy
GORD 48 (12.57) 41 (10.28) 8 (12.31)
Helicobacter eradication 6 (1.57) 1 (0.25) 4 (6.15)
Peptic ulcer long-term
treatment
40 (10.47) 43 (10.78) 1 (1.54)
Prevention
Stress ulcer prophylaxis 15 (3.93) 8 (2.01) 0 (0.00)
Other—”gastro protection”
(e.g. ASA, NSAID,
polypharmacy)
273 (71.47) 296 (74.19) 52 (80.00)
ASA 47 (12.3) 118 (29.57) 27 (41.54)
Clopidogrel no info 48 (12.03) 42 (64.62)
ASA and Clopidogrel no info 40 (10.03) 18 (27.69)
NSAID 64 (16.75) 52 (13.03) 3 (4.62)
Anticoagulants* no info no info 4 (6.15)
Missing answer – 10 (2.51) –*Low molecular weight heparins, vitamin K antagonist, novel anticoagulants.
PPI, proton pump inhibitor; SD, standard deviation; GORD, Gastro-oesophageal reflux
disease; ASA, acetyl salicylic acid; NSAID, non steroid anti-inflammatory drugs.TABLE 6 | Prescribed pantoprazole daily doses in patient-level surveys.
Survey 1 Survey 2 Survey 3
Number of patients
(%)
N=366
(100)
N=384
(100)
N=51
(100)
Pantoprazole
daily dose
20 mg
(low dose/on demand
dose)
51 (13.93) 72 (18.75) 12 (23.53)
40 mg
(standard dose-WHO
DDD)
177
(48.36)
174
(45.31)
22 (43.14)
60 mg 2 (0.55)
80 mg (high dose) 135
(36.80)
136
(35.42)
15 (29.41)
120 mg 1 (1.96)
160 mg 1 (0.26)
missing data 1 (0.27) 1 (0.26) 1 (1.96)September 2020 | Volume 11 | Article 552102
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Most patients in this study received PPI as a prophylactic agent.
According to the literature, the most common drivers of PPI
misuse are related to unjustified, long-term prophylactic use:
prevention of gastro-duodenal ulcers in patients without risk
factors for gastric injury (NSAID users, antiplatelet/
anticoagulant therapy); stress ulcer prophylaxis in non-
intensive care units; steroid therapy alone; selective serotonin
reuptake inhibitor therapy alone (Pottegard et al., 2016; Savarino
et al., 2018a). In the Icelandic study, nearly half of the patients
used PPI concurrently with acetyl salicylic acid, NSAID, platelet
inhibitors, or oral anticoagulant (Halfdanarson et al., 2018). The
concurrent use of ulcerogenic agents and/or anticoagulant/
antiplatelet drugs was also considerable in the PPI users in our
study (see Table 5). On the other hand, in Survey 2, out of the
399 PPI users, 66 patients (16,5%) did not have any therapeutic
indication for PPI use, and also had not used any potentially
ulcerogenic or anticoagulant/antiplatelet drug, which is a clear
evidence of PPI overuse. Similarly, in Survey 3 only a minority of
patients taking clopidogrel received NSAID treatment, or had
had a history of peptic ulcer/bleeding, or were on dual
antiplatelet therapy, which may question the need for PPI use.
Other studies from inpatients reported a high discordance
from evidence-based indications of PPI use (Pillans et al., 2000;
Chia et al., 2014; Meli et al., 2015; Lodato et al., 2016; Pujal
Herranz, 2016; van den Bemt et al., 2016; Ying et al., 2019). In the
expert review of Savarino et al. PPIs are considered as “harmless,
cheap remedy for any digestive problems by doctors” (Savarino
et al., 2018a). Moreover, as a Chinese article revealed,
procurement incentives for doctors may also play a role (Zeng
et al., 2015) in the non-prudent prescribing of PPIs.
The present study has some limitations inherent in the
database and the study design. The National Health Insurance
Fund database contains drug dispensing data for only prescribed
and reimbursed drugs. As over the counter PPI products and
prescribed but non-reimbursed PPI products are not included in
the database, the scale of nationwide use of PPIs has been
underestimated. In the patient-level point prevalence survey
the prevalence of PPI use was assessed on the given study days
and from hospitals where daily drug dispensation is supervised
by a pharmacist. This study design did not allow for the precise
determination of hospital initiation of PPI use, which could
occur during the hospitalisation but after the specific study day.
As hospital PPI initiation could differ in hospitals without ward
pharmacists, our results cannot be extrapolated to all Hungarian
hospitals. On the other hand, this study focused on chronic PPI
use, initiated before hospital admission. As we excluded specific
gastroenterological units and did not apply any specific
inclusion criteria for the inpatients, we believe that results of
the multicenter surveys are generalizable for the hospitalized
patients in Hungary. Also, much of the information (indication,
duration, initiation, de-prescribing) were gained from the
patients, so recall bias should be considered. In Survey 3, due
to the low number of patients, the data on de-prescribing should
be regarded as a signal, not as a valid, generalizable assessment.
In the absence of national and local guidelines on PPI use, we didFrontiers in Pharmacology | www.frontiersin.org 7not aim to precisely determine the appropriateness of
PPI therapy.CONCLUSION
Our data suggests that Hungarian patients may receive PPIs in high
doses and for a long time. PPI use beyond the recommended
indications were found, so PPI treatment should be initiated more
cautiously for specific indications, and PPI dosing and duration of
therapy should be reconsidered regularly.DATA AVAILABILITY STATEMENT
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